Methylenedioxyanilino-quinazolines and -cyanoquinolines as inhibitors of MEK and/or Src

Abstract

Novel methylenedioxyanilino-quinazolines and -cyanoquinolines with an acetylene side chain on the aniline are claimed as inhibitors of mitogenactivated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) and/or Src. These potential antitumour agents are the most recent in a series of applications from AstraZeneca.